In vivo evidence has shown that oxytocin pre-treatment reduced the inflammatory microenvironment generated by ox-Low Density Lipoprotein (ox-LDL) in the hippocampus of mice with craniopharyngioma, which subsequently improved cognitive function as measured by faster escape latencies in the Morris Water Maze Test (Wang et al., 2023). Here, OXT is linked to craniopharyngioma.